絞り込み

17443

広告

Remoxipride in schizophrenia: effects on plasma prolactin.

著者 Chouinard G , Turnier L , Kallai-Sanfacon MA この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (5view , 0users)

Medical

Twenty hospitalized schizophrenic patients were treated for six weeks with remoxipride. All patients completed the clinical trial. Ten patients showed marked improvement in schizophrenic symptoms, and all patients showed a statistically significant (p less than .05) reduction in the mean score for CGI severity of illness and BPRS total score. Remoxipride was found to cause less parkinsonism than the prior neuroleptic therapy and appeared to have little masking effect on tardive dyskinesia. The absence of steady state plasma prolactin elevations differentiates remoxipride from classical neuroleptics while the peak increase of plasma prolactin concentrations 1 hour after drug intake confirms that remoxipride has some effect in the pituitary system. Results from this study underline the importance of D2 receptor blockade in achieving an antischizophrenic effect.
PMID: 2868493 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード